SMN1 and proximal spinal muscular atrophy: For the treatment of SMA, caused by homozygous deletion of the SMN1 gene, intrathecal administration of a modified ASO nusinersen increases the amount of the SMN protein in alpha motor neurons by altering the distribution of alternatively spliced transcripts from the SMN2 gene [50].